Mainz Biomed(MYNZ) - 2022 Q2 - Earnings Call Presentation

Colorectal Cancer (CRC) & Market Opportunity - Colorectal cancer is the 2nd most lethal cancer in the US, but early detection provides over 90% 5-year survival rates[8] - The U S market potential is over 52 million tests per year for individuals over 45, based on recent FDA guidance[8] - The estimated market opportunity in the U S is $3 7 billion[15] - Approximately 38 8% of Americans aged 50 to 75 have never been screened for CRC[14] ColoAlert & Pancreatic Cancer (PANCAlert) - ColoAlert is a non-invasive, at-home test with 92% specificity and 85% sensitivity, designed to be easier to administer than Exact Science's ColoGuard and more accurate than FIT[8] - ColoAlert demonstrated up to 60% fewer missed cases compared to the fecal immunochemical test (FIT)[17] - Mainz BioMed is developing proprietary genetic testing methods for pancreatic cancer, with a potential for over 50 million tests per year in Europe alone[31] Company & Financials - Mainz BioMed is aiming to become a leading provider of easy-to-use diagnostic solutions[5] - The company had $29 0 million in cash on hand as of April 30, 2022[38] - The company's market capitalization (basic) was $173 7 million as of April 30, 2022[38]